Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial

Fahlén, Mia; Fornander, Tommy; Johansson, Hemming; Johansson, Ulla; Rutqvist, Lars‐Erik; Wilking, Nils; Schoultz, E. von

doi:10.1016/j.ejca.2012.07.003

Cited by 127 publications

(108 citation statements)

References 26 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…(LIBERATE), and Stockholm trials, of HRT treatment in women with a previous history of breast cancer had to be halted due to concerns about the safety of the treatment following early followups (40)(41)(42). Although -even in healthy individuals -late onset of menopause, early menses, and HRT are all associated with a risk in developing breast cancer (43,44), cyclical expansion of the mammary gland (25) could hasten the acquisition of secondary mutations that drive relapse in breast cancer survivors harboring a mutation-permissive metabolism.…”

Section: Discussionmentioning

confidence: 99%

Metabolic shifts in residual breast cancer drive tumor recurrence

Havas¹,

Milchevskaya²,

Radic³

et al. 2017

Journal of Clinical Investigation

143

127

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Metabolic shifts in residual breast cancer drive tumor recurrence

Havas¹,

Milchevskaya²,

Radic³

et al. 2017

Journal of Clinical Investigation

143

127

View full text Add to dashboard Cite

“…However, in breast cancer patients there is understandable reticence around the use of estrogen-based therapy, as these products are associated with increasing serum levels of estradiol, possibly increasing the risk of breast cancer recurrence [7][8][9].…”

mentioning

confidence: 99%

Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials

Mazzarello

Hutton

Ibrahim

et al. 2015

Breast Cancer Res Treat

View full text Add to dashboard Cite

Symptoms of urogenital atrophy are common in breast cancer survivors. Its optimal management is currently unknown. A systematic review of randomized controlled trials (RCTs) evaluating treatments for urogenital atrophy in breast cancer patients was performed. EMBASE, Ovid Medline and the Cochrane Library were searched from 1946 to November 2014. Outcomes included improvements in both vaginal symptoms (e.g., dryness, pain, dyspareunia and itching) and vaginal hormone response measured by validated scales [e.g., Vaginal Health Index (VHI) and Vaginal Maturation Index (VMI)]. Of 430 unique citations identified, 4 studies (n = 196) met inclusion criteria. Interventions included pH-balanced gel, Replens(®), lidocaine, Estring(®) and Vagifem(®). Sample sizes ranged from 7 to 98 patients. Given the heterogeneity of the studies, a narrative synthesis of results was performed. One study of 98 patients suggested that vaginal pH-balanced gel (mean VHI 5.00 ± 0.816, mean VMI 51.18 ± 3.753) was more efficient than placebo (VHI 16.98 ± 3.875, p < 0.001, VMI 47.87 ± 2.728, p < 0.001) at 12 weeks in providing vaginal symptom relief. In patients who used lidocaine, 90 % had reduced dyspareunia compared to saline in a study of 46 patients. Although increased serum estradiol occurred, both Estring(®) and Vagifem(®) were shown to improve quality of life and VMI in a study of seven patients. Treatment of urogenital atrophy remains a challenging issue and there is a paucity of RCT evidence addressing this knowledge gap. It is evident that more prospective trials are needed.

show abstract

“…There were two studies using 'standard HT' regimens of conjugated equine oestrogens and low-dose MPA, the Stockholm study (27) and the HABITS study (28). Both were terminated early.…”

Section: Hormone Therapymentioning

confidence: 99%

“…However, a few years ago, a number of clinical trials were performed to examine the safety of using HT after a diagnosis of breast cancer (23,27,28,29).…”

Section: Hormone Therapymentioning

confidence: 99%

ENDOCRINE DILEMMA: Managing menopausal symptoms after breast cancer

Eden

2016

European Journal of Endocrinology

View full text Add to dashboard Cite

Managing the symptoms of menopause after a diagnosis of breast cancer offers some unique clinical challenges. For some women, vasomotor symptoms can be severe and debilitating, and hormone therapy is at least relatively contraindicated. Non-oestrogen therapies for hot flushes include SSRIs, clonidine, gabapentin and perhaps black cohosh extracts. Vulvovaginal atrophy can usually be alleviated by simple moisturizers, although some may need specialized physiotherapy such as vaginal dilators. In a small number, topical oestrogens may be the only treatment that works. The CO 2 laser may be a novel, non-oestrogen therapy to alleviate this unpleasant symptom. Bone loss can be accelerated in some patients on AIs or those who had early menopause induced by chemotherapy.

show abstract

Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial

Cited by 127 publications

References 26 publications

Metabolic shifts in residual breast cancer drive tumor recurrence

Metabolic shifts in residual breast cancer drive tumor recurrence

Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials

ENDOCRINE DILEMMA: Managing menopausal symptoms after breast cancer

Contact Info

Product

Resources

About